Skip to content
value.today

Blade Therapeutics, Inc.

Formerly FibroRX, Inc.

Total raised
$65 M
2 rounds on record
Latest round
$38 M
Nov 2018
First round on record
Jun 2016
Today
Private
No later event on record

Funding rounds

2 counted as startup funding, 1 other private sales on record. Open the number of investors for the round's details.

Funding rounds of Blade Therapeutics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Sep 2019$12 MIssued in a merger or acquisition$10 to $50 million

Blade Therapeutics, Inc.: Private sale, Sep 2019

Investors in this round

21 investors had bought by the notice of Oct 24, 2019: 21 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$12 M of $24 M offered; $12 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Gary B. Patou · Executive Officer
  • M. Shirley Chiang · Executive Officer
  • Prabha Shirley Ibrahim · Executive Officer
  • Wendye Rae Robbins · Executive Officer, Director
  • Cameron Shirley Wheeler · Director
  • James B. Scopa · Director
  • Lloyd B. Klickstein · Director
  • Luke Shirley Evnin · Director
  • Peter Shirley Van Vlasselaer · Director
  • Rana Rae Al-Hallaq · Director
  • William V. Slattery · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Wendye Rae Robbins, President & CEO. Source: SEC Form D, newest notice filed Oct 24, 2019. Read the notice at the SEC.

equitySEC
Nov 2018$38 MNo. 2$10 to $50 million

Blade Therapeutics, Inc.: Raise no. 2, Nov 2018

Investors in this round

10 investors had bought by the notice of Oct 24, 2019: 10 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$38 M of $50 M offered; $12 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Gary B. Patou · Executive Officer
  • M. Shirley Chiang · Executive Officer
  • Prabha Shirley Ibrahim · Executive Officer
  • Wendye Rae Robbins · Executive Officer, Director
  • Cameron V. Wheeler · Director
  • James B. Scopa · Director
  • Lloyd B. Klickstein · Director
  • Luke Shirley Evnin · Director
  • Peter V. Van Vlasselaer · Director
  • Rana Rae Al-Hallaq · Director
  • William V. Slattery · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Wendye Rae Robbins, President & CEO. Source: SEC Form D, newest notice filed Oct 24, 2019. Read the notice at the SEC.

equity, optionsSEC
Jun 2016$27 MNo. 1$10 to $50 million

Blade Therapeutics, Inc.: Raise no. 1, Jun 2016

Investors in this round

10 investors had bought by the notice of Jun 20, 2016: 10 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$27 M of $45 M offered; $18 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Wendye Robbins · Executive Officer, Director
  • Cameron Wheeler · Director
  • Elaine Jones · Director
  • James Scopa · Director
  • Luke Evnin · Director
  • Peter van Vlasselaer · Director
  • William Slattery · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Wendye Robbins, President. Source: SEC Form D, newest notice filed Jun 20, 2016. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Blade Therapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (Oct 2019).

    SEC Form D · Oct 2019

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Oct 2019

That is all the official record says: Blade Therapeutics, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Blade Therapeutics, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 10 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Blade Therapeutics, Inc.
NameRoleNamed in
Gary B. PatouExecutive officerOct 2019
M. Shirley ChiangExecutive officerOct 2019
Prabha Shirley IbrahimExecutive officerOct 2019
Wendye Rae RobbinsExecutive officerOct 2019
Wendye RobbinsExecutive officerJun 2016
Cameron Shirley WheelerDirectorOct 2019
Cameron V. WheelerDirectorOct 2019
James B. ScopaDirectorOct 2019
Lloyd B. KlicksteinDirectorOct 2019
Luke Shirley EvninDirectorOct 2019
Peter Shirley Van VlasselaerDirectorOct 2019
Peter V. Van VlasselaerDirectorOct 2019
Rana Rae Al-HallaqDirectorOct 2019
Wendye Rae RobbinsDirectorOct 2019
William V. SlatteryDirectorOct 2019
Cameron WheelerDirectorJun 2016
Elaine JonesDirectorJun 2016
James ScopaDirectorJun 2016
Luke EvninDirectorJun 2016
Peter van VlasselaerDirectorJun 2016
Wendye RobbinsDirectorJun 2016
William SlatteryDirectorJun 2016